Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies

Clinical Infectious Diseases

Volumn 56, Issue 7, 2013, Pages 943-950

  Al Shuaibi, Munirah ^a   Bahu, Ramez R ^a   Chaftari, Anne Marie ^a   Al Wohoush, Iba ^a   Shomali, William ^a   Jiang, Ying ^a   Debiane, Labib ^a   Raad, Sammy ^a   Jabbour, Joseph ^a   Al Akhrass, Fady ^a   Hachem, Ray Y ^a   Raad, Issam ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Febrile; Hematologic malignancy; Infections; Pro adrenomedullin (proADM)

Indexed keywords

ANTIBIOTIC AGENT; PROADRENOMEDULLIN; PROCALCITONIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; BACTERIAL INFECTION; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCHOOL CHILD; SEPSIS; STEM CELL TRANSPLANTATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT RESPONSE;

ADOLESCENT; ADRENOMEDULLIN; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; CALCITONIN; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; FEVER OF UNKNOWN ORIGIN; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; YOUNG ADULT;

EID: 84875018410     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1029     Document Type: Review

References (46)

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56-e93.
2. Limper M, de Kruif MD, Duits AJ, Brandjes DP, van Gorp EC. The diagnostic role of procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J Infect 2010; 60: 409-16.
3. Sepkowitz KA. Treatment of patients with hematologic neoplasm, fever, and neutropenia. Clin Infect Dis 2005; 40(suppl 4):S253-6.
4. Bleeker-Rovers CP, Vos FJ, de Kleijn EM, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) 2007; 86: 26-38.
5. Mueller PS, Terrell CL, Gertz MA. Fever of unknown origin caused by multiple myeloma: a report of 9 cases. Arch Intern Med 2002; 162: 1305-9.
6. Vanderschueren S, Knockaert D, Adriaenssens T, Demey W, Durnet A, Blockmans D, Bobbaers H. From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med 2003; 163: 1033-41.
7. Odabasi Z, Mattiuzzi G, Estey E, et al. β-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
8. Senn L, Robinson JO, Schmidt S, et al. 1,3-β-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46: 878-85.
9. Prat C, Sancho JM, Dominguez J, et al. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 2008; 49: 1752-61.
10. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Müller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005; 9:R37-45.
11. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004; 23: 539-44.
12. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206-17.
13. Knudsen JB, Fuursted K, Petersen E, Wierup P, Molgaard H, Poulsen SH, Egelblad H. Procalcitonin in 759 patients clinically suspected of infective endocarditis. Am J Med 2010; 123: 1121-7.
14. Novotny AR, Emmanuel K, Hueser N, et al. Procalcitonin ratio indicates successful surgical treatment of abdominal sepsis. Surgery 2009; 145: 20-6.
15. Massaro KS, Costa SF, Leone C, Chamione DA. Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 2007; 7: 137.
16. Christ-Crain M, Morgenthaler NG, Struck J, et al. Mid-regional proadrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005; 9:R816-24.
17. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 2011; 9: 107.
18. Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM. Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department. Am J Clin Pathol 2011; 135: 182-9.
19. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008; 36: 396-407.
20. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164: 396-402.
21. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitoninbased guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059-66.
22. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007; 30: 556-73.
23. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011; 171: 1322-31.
24. Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections - hope for hype? Swiss Med Wkly 2009; 139: 318-26.
25. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10:pR96.
26. Coutinho T, Al-Oman M, Mosley TH Jr, Kullo IJ. Biomarkers of left ventricular hypertrophy and remodeling in blacks. Hypertension 2011; 58: 920-5.
27. Hachem R, Al Wohoush I, Jiang Y, Chaftari A, Raad I. Comparing biomarker procalcitonin (PCT) and pro-adrenomedullin (proADM) as a predictor of response to antibiotics in critically ill cancer patients with bacteremia and sepsis. In: 49th IDSA Annual Meeting. 2011. Boston.
28. Brahms. MR-proADM Kryptor "Instructions for Use." In: Thermo Scientific Brahms LLC. Middletown, VA, 2011.
29. Brahms. PCT sensitive Kryptor "Instructions for Use." In: Thermo Scientific Brahms LLC, Middletown, VA, 2011.
30. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365: 63-78.
31. Vincent JL, Martinez EO, Silva E. Evolving concepts in sepsis definitions. Crit Care Clin 2009; 25:p665-75, vii.
32. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-6.
33. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamarellou N. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 2001; 32: 1718-25.
34. Chirouze C, Schuhmacher H, Rabaud C, et al. Low serum procalcitonin level accurately predicts the absence of bacteremia in adult patients with acute fever. Clin Infect Dis 2002; 35: 156-61.
35. Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 1999; 18: 283-5.
36. Engel A, Steinbach G, Kern P, Kern WV. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 1999; 31: 185-9.
37. Juutilainen A, Hämäläinen S, Pulkki K, Kuittinen T, Nousiainen T, Jantunen E, Koivula I. Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis. Leuk Lymphoma 2011; 52: 2349-55.
38. Koivula I, Hämäläinen S, Jantunen E, Pulkki K, Kuittinen T, Nousiainen T, Juutilainen A. Elevated procalcitonin predicts gram-negative sepsis in haematological patients with febrile neutropenia. Scand J Infect Dis 2011; 43: 471-8.
39. Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U. Procalcitonin in pediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumor necrosis factor receptor II. Br J Haematol 2000; 111: 1093-102.
40. Robinson JO, Lamoth F, Bally F, Knaup M, Calandra T, Marchetti O. Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One 2011; 6:pe18886.
41. Albrich WC, Dusemond F, Ruegger K, et al. Enhancement of CURB65 score with pro-adrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis 2011; 11: 112.
42. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010; 14: 203.
43. Blijlevens NM, Donnelly JP, Meis JF, De Keizer MH, De Pauw BE. Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol 2000; 7: 889-92.
44. Wang RL, Kang FX. Prediction about severity and outcome of sepsis by pro-atrial natriuretic peptide and pro-adrenomedullin. Chin J Traumatol 2010; 13: 152-7.
45. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93.
46. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomized controlled trial. Lancet 2010; 375: 463-74.